Dermata Therapeutics Stock Today
| DRMA Stock | USD 1.24 -0.02 -1.59% |
Performance
| Odds Of Distress
|
Dermata Therapeutics is quoted at $1.24 as of April 25, 2026, recording a 1.59% decrease for the day. Market-implied stability metrics indicate that Dermata Therapeutics has a substantially elevated probability of financial distress over the coming years. Over the last 90 trading days, it has delivered negative risk-adjusted returns. The performance scores are measured across the period from January 25, 2026 to April 25, 2026. Learn more.
IPO Date 13th of August 2021 | Asset Type Stock | Category Healthcare | Classification Health Care |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Stock Highlights
Dermata Therapeutics (DRMA) is listed on NASDAQ Exchange in USA. Dermata Therapeutics is part of the Biotechnology industry. The company conducts business in the Biotechnology sector. Dermata Therapeutics now stands at 5.09 M in market capitalization, which maps the company to the nano-cap universe of biotechnology companies. Complementary market value signals include a workforce of about 9 people and about 4.02 M shares outstanding. The company has 264.04 K shares sold short (0.12 days to cover). Dermata Therapeutics operates as a research-driven pharmaceutical developer where revenue is driven by drug pipeline progression, regulatory approvals, and patent-protected sales. Net Loss for the year was -7.56 B with profit before overhead, payroll, taxes, and interest of 0. Dermata Therapeutics financial stability analysis Ownership Allocation Dermata Therapeutics carries a notable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Check Dermata Ownership DetailsStock Notable Updates
| Legal Name | Dermata Therapeutics Inc |
| Founder and President, CEO & Chairman | Gerald Proehl |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare, (View all Sectors) |
Latest disclosures for Dermata Therapeutics show a Return On Capital Employed of -0.1%, a Return On Equity of -0.1%, and a Return On Tangible Assets of -0.1%. Dermata Therapeutics financial framework combines liquidity support with pressured financial positioning. The earnings picture reflects near-term margin compression relative to deployed assets.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Current Liabilities | 1.5 M | 1.6 M |
|
| |||||
| Total Assets | 8.3 B | 7.9 B |
|
| |||||
| Total Current Assets | 7.9 B | 7.5 B |
|
|
Current Assets
Latest disclosures for Dermata Therapeutics show $8.3 billion in Total Assets, a Return On Tangible Assets of -0.1%, and a Debt To Assets of 553.0%. $7.3 million in Net Tangible Assets round out the key financial metrics view for Dermata Therapeutics.
Earnings per Share Projection vs Actual
The spread between high and low EPS estimates for Dermata Therapeutics captures the degree of analyst disagreement on near-term earnings. The forward EPS estimate sits alongside trailing results as a dual lens on Dermata Therapeutics' earnings trajectory.
Consensus EPS projections for Dermata Therapeutics' are based on current analyst assumptions and may be revised. Reported EPS TTM is historical and should not be read as a forecast.
Top Institutional Holders
Institutional Holdings in Dermata Therapeutics captures the equity stake owned by major financial organizations. Institutions may purchase large blocks of Dermata Therapeutics' outstanding shares and exert considerable management influence.| Instituion | Recorded On | Shares | |
| Ubs Group Ag | 2025-09-30 | 10 K | |
| Tower Research Capital Llc | 2025-12-31 | 2 K | |
| Sbi Securities Co Ltd | 2025-12-31 | 101 | |
| Bank Of America Corp | 2025-09-30 | 4.0 | |
| Geode Capital Management, Llc | 2025-09-30 | 0.0 | |
| Jones Financial Companies Lllp | 2025-09-30 | 0.0 |
Dermata Therapeutics Historical Income Statement
Net Interest Income stood at 215,041 as of December 31, 2025. As of last week, Depreciation And Amortization is at approximately 15.1 M per recent reporting, while Selling General Administrative is at about 3.9 M per recent reporting. View More FundamentalsDermata Therapeutics Against Markets
Stock Overview, Methodology & Data Sources
The company was incorporated in 2014 and is headquartered in San Diego, California. Dermata Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. Dermata Therapeutics employs 9 people. Headquarters are in 3525 Del Mar Heights Rd., San Diego, CA, United States, 92130. Current valuation profile shows market cap 5.09 M, P/B 0.84, ROE -1.94%. Dermata Therapeutics operates in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Financial reporting is combined with risk and trading context. Lower liquidity environments can sometimes affect short-term price stability.
Methodology
Unless otherwise specified, financial data for Dermata Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Dermata (USA Stocks:DRMA) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. All analytics presented are generated using Macroaxis quantitative models that incorporate financial statement analysis, market data, and risk metrics to ensure consistency and comparability. Assumptions: The dataset for Dermata Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Dermata Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Editorial review and methodology oversight provided by: Rifka Kats, Member of Macroaxis Editorial Board
Dermata Therapeutics Corporate Management
| Maria Munera | Senior Vice President of Regulatory Affairs & Quality Assurance | Profile | |
| Christopher MPH | Senior VP & Chief Development Officer | Profile | |
| Kyra Peckaitis | Vice President of Marketing | Profile | |
| Sean Proehl | Associate General Counsel | Profile |